ZyVersa Therapeutics, Inc. ZVSA
0.10
0.00
0.00%
as of 24 Sep
- Market cap
- $970.0K
- P/E
- 0.0×
Follow ZVSA
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 0.04 | 0.06 | 0.78 | 0.33 | 0.15 | 0.03 |
Net Debt/EBITDA |
— | (0.31) | 0.04 | 0.43 | 0.03 | 0.17 | 0.00 |
Debt/Assets |
0.00% | 556.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | (0.45) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.41 | 0.63 | 0.20 | 0.08 | 0.80 | 0.21 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | 74.44% | (55.60%) | (191.89%) | (96.10%) | 1,289.40% | |
| — | (3,699.88%) | (892.39%) | (40.35%) | (151.11%) | (44.08%) | (238.24%) | |
ROIC |
— | 0.00% | 0.00% | (9.22%) | (848.52%) | (81.75%) | 0.00% |
Return on Tangible Assets |
— | 176.67% | 63.22% | 1,334.95% | 1,554.49% | 98.93% | 201.44% |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.94 | 0.84 | 0.91 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (11.28) | (73.46) | (189.48) | (89.44) | (6.77) | (0.86) |
Cash per Share |
— | 0.38 | 4.76 | 228.77 | 32.18 | 1.38 | 0.02 |
Shareholders Equity per Share |
— | (18.38) | (185.69) | 3,862.91 | 113.59 | 7.67 | (2.08) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (18.38) | (185.69) | 3,862.91 | 113.59 | 7.67 | (2.08) |
Free Cash Flow |
— | (5.25) | (5.08) | (4.89) | (8.72) | (7.52) | (5.11) |
Working Capital |
— | (7.22) | (12.81) | (1.83) | (6.84) | (9.52) | (12.39) |
Net Current Asset Value |
— | (8.90) | (13.15) | (12.48) | (7.69) | (10.37) | (12.39) |
| Other line items | |||||||
Quick Ratio |
— | 0.02 | 0.02 | 0.72 | 0.31 | 0.14 | 0.01 |
Depreciation/Fixed assets |
— | 0.27 | 11.85 | 2.88 | 1,725.42 | 0.00 | — |
Cash ROIC |
— | 115.85% | 40.82% | (4.65%) | (61.41%) | (74.84%) | 41.63% |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 81,142.31 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (11.28) | (73.46) | (189.48) | (89.44) | (6.77) | (0.86) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | — | 2.16 | 4.01 | 7.23 | 8.88 | 9.73 |
Average Assets |
— | 0.34 | 0.91 | 59.82 | 70.31 | 21.36 | 10.47 |
Average Common Equity |
— | — | (10.86) | 43.42 | 55.37 | 9.80 | (1.94) |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates